SequelSEC

Bodhi Tree Biotechnology Inc BDTB

Services-Management Consulting Services · CIK 0002041531 · Fiscal year ends 0930

Revenue
$17.00K
Fiscal year ended 2025-09-30
Operating income
-$147.62K
Fiscal year ended 2025-09-30
Free cash flow
Unavailable
Fiscal year ended 2025-09-30

Bodhi Tree Biotechnology Inc (BDTB) reported revenue of $17.00K and net income of -$149.67K for the fiscal year ended 2025-09-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Bodhi Tree Biotechnology Inc’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Management Consulting Services.

Income

Bodhi Tree Biotechnology Inc income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Revenue$17.00K
Cost of revenueUnavailable
Gross profitUnavailable
Operating income-$147.62K
Net income-$149.67K
Research & developmentUnavailable
Weighted-average diluted sharesshares 25.44M
Pretax income-$147.62K
Income tax expense$2.05K
Diluted EPS$-0.01
Selling, general & administrativeUnavailable
General & administrative$164.62K
Selling & marketingUnavailable

Balance

Bodhi Tree Biotechnology Inc balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Cash & equivalentsUnavailable
Total assets$119.16K
Current assetsUnavailable
Total liabilitiesUnavailable
Current liabilitiesUnavailable
Total equity incl. NCI$119.16K
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivableUnavailable
GoodwillUnavailable
Long-term debtUnavailable
Accounts payableUnavailable

Cash flow

Bodhi Tree Biotechnology Inc cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Operating cash flow-$150.17K
Capital expendituresUnavailable
Investing cash flowUnavailable
Financing cash flowUnavailable
Net change in cashUnavailable
Stock-based compensationUnavailable
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortizationUnavailable

Derived

Bodhi Tree Biotechnology Inc derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-09-30
Free cash flowUnavailable
Gross marginUnavailable
Operating margin-868.3%
FCF marginUnavailable
SBC / revenueUnavailable
Current ratioUnavailable
Revenue YoY growthUnavailable
Net margin-880.4%
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open BDTB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-14View SEC filing
10-Q · Filed 2026-05-14View SEC filing
10-Q · Filed 2026-02-13View SEC filing
10-K · Filed 2025-12-29View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-Q · Filed 2025-05-20View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.